Why Does Chlortetracycline Soluble Powder Degrade Above pH 7.0 in Poultry Drinking Water?

Water-soluble powder intended for flock medication via proportioner or tank administration is formulated around the pH-dependent solubility of chlortetracycline hydrochloride. At drinking water pH values between 4.0 and 5.5, the hydrochloride salt dissolves rapidly and remains sufficiently ionised for dispersion; above pH 7.0, soluble carbonate and bicarbonate species replace chloride in the dissolution layer and the parent molecule partitions into less bioavailable degradation products, particularly epi-anhydrochlortetracycline. The production flow for a 10–20% w/w water-soluble powder therefore uses a dry blend of chlortetracycline hydrochloride with an acidic buffer system, typically citric acid monohydrate and sodium citrate dihydrate, and a water-soluble carrier such as lactose monohydrate or sorbitol. Addition rate to the final flock water line is not fixed; it is calculated from daily water consumption per bird and bodyweight, with registered formulations commonly delivering 20–50 mg chlortetracycline per kg bodyweight per day over a 3–5 day treatment period, while stock powder dilution is adjusted by proportioner setting from 0.05–0.2% w/v. This product class must meet the same residue control anchors as feed premixes: Commission Regulation (EU) No 37/2010 for poultry muscle, liver, and egg withdrawal periods, and 21 CFR 558.128 or the 21 CFR 520 series for approved drinking water administration in the United States, depending on species and route. Manufacturing is typically a fluid-bed granulation step at inlet air temperature 50–60°C, spraying a binder solution of povidone K30 at 3–5% w/w, followed by drying to residual moisture below 2% and packaging in aluminium foil sachets with desiccant. Granulation is preferred to simple blending because chlortetracycline hydrochloride has poor flow and segregates from lactose at the cone outlet; a granulated product with bulk density 0.55–0.65 g/mL maintains content uniformity across a 10 kg sachet fill. Dissolution is tested in 500 mL of water at 20°C, with release criteria specifying 90% dissolved within 15 minutes under agitation. Terminal finished product types are water-soluble powder sachets, powdered oral drenches, and proportioner solutions reconstituted at the farm, but not slow-release or oil-based suspensions, because oily carriers suppress the ionisation required for rapid flock ingestion. Hard water with total hardness above 250 mg/L CaCO3 shortens the chemical stability of stock solutions; chlorinated water does not accelerate loss as strongly as alkaline pH but can produce chlorinated by-products during extended holding. Stock solutions are consumed within 24 hours and prepared in plastic rather than galvanised steel, because zinc and iron from contact surfaces chelate tetracycline and form coloured insoluble complexes.

In a swine feed mill receiving chlortetracycline hydrochloride as the active component of a 20% or 25% active premix, the first technical boundary is not bulk carrier blending but the assay control of a hygroscopic, light-sensitive tetracycline intermediate. When the API is weighed as a 20% or 25% active premix, the concentrate is pre-screened through a 40-mesh sieve before geometric dilution into a carrier such as calcium carbonate, ground limestone, or solvent-extracted soybean meal. A typical approved addition for growing swine begins at 100–400 mg chlortetracycline per kg of complete feed where authorised by species and disease claim under the label; the exact inclusion is taken from the registered feed additive dossier rather than from a general rule. Carryover control is set at no more than 1% of the lowest approved dose for non-target feed lines, which translates into direct cleaning validation acceptance limits for ribbon mixers, bucket elevators, and drag conveyors. Industry compliance for this route is anchored by 21 CFR 558.128 for approved uses in swine feeds, with Category II medicated feed restrictions under 21 CFR 558.4, while EU feed business operators operate under Regulation (EU) 2019/6 and Commission Regulation (EU) No 37/2010 for residue control in swine tissues. GMP boundaries follow 21 CFR Part 225 and Part 226 for Type B and Type C medicated feed mills. Mixing is performed in a horizontal ribbon mixer with a fill ratio of 60–75% of designed volume to maintain a coefficient of variation below 5% after a 3–5 minute dry cycle; the API pre-blend is prepared as a 1:10 dilution, then a 1:100 dilution before addition to the final batch, because direct addition of the 20% premix to a 2-tonne batch produces assay hot spots at the die. Pelleting may follow only if the conditioner temperature is held below 75°C and residence time does not exceed 45 seconds; above this window the 4-epimer and anhydrotetracycline degradation pathway accelerates and label assay loss can exceed 15%. Post-processing handling before bagging requires residual moisture below 10% for the finished meal and below 12.5% for the premix; bulk storage in steel bins above 60% RH introduces caking and assay loss due to hygroscopic uptake. The accepted in-plant method for assay verification is liquid chromatography against a current pharmacopoeial reference standard, not simple UV, because fermentation-derived chlortetracycline contains related tetracycline equivalents that overreport assay by non-specific methods. Destruction of retained medicated feed samples and flush material follows national carryover directives; in the EU, the sequence of flushing is documented in the feed safety management system, while in the United States the finished medicated feed is released against 21 CFR 558.128 label conditions before shipment. Terminal finished product types from this scenario are medicated complete meal feeds, pelleted grower/finisher feeds, top-dress powders, and Type B intermediate premixes that downstream mills dilute to Type C medicated feeds.

Dry Granulation and Direct Compression Limits for Companion Animal Tablets and Capsules

Chlortetracycline hydrochloride tablets and capsules for companion animal oral administration are produced without wet granulation wherever formulators can maintain flowability by dry granulation or direct compression. The tetracycline ring is susceptible to hydrolysis in the presence of free water, and oven drying accelerates the formation of 4-epichlortetracycline and anhydrochlortetracycline, both of which are counted as impurities in current pharmacopoeial monographs. Tablet manufacture therefore begins with the API passed through a 60-mesh screen, typically at 70–80% w/w of the core, blended with microcrystalline cellulose at 10–25% w/w, crospovidone at 2–5% w/w, and sodium stearyl fumarate at 1–2% w/w. The blend is dry granulated in a roller compactor operating at roll pressure 30–60 kN, then milled through a 1.0 mm screen to produce a free-flowing granulate with bulk density 0.52–0.68 g/mL. Capsule filling uses the same granulate, with API particle size controlled at D90 below 200 µm to avoid fill-weight fluctuation and content uniformity failure at 50 mg, 100 mg, and 250 mg strengths. Tablet hardness is maintained at 8–15 kP for conventional film-coated tablets; hardness above 20 kP slows dissolution in older animals but may be needed for chewable forms. Compliance is anchored to the current USP and Ph. Eur. monographs for chlortetracycline hydrochloride, USP <905> uniformity of dosage units, USP <711> dissolution, and 21 CFR Part 211 for finished pharmaceutical manufacture. In the EU, the veterinary product must be authorised under Regulation (EU) 2019/6 and meet the Ph. Eur. general chapter for dissolution as specified in the dossier. The addition ratio in a tablet core is not freely adjustable; it is fixed by the intended dose per tablet and by the bioavailability of the selected salt form in dogs or cats. A pre-formulation screen with 50 mg and 100 mg tablets against the reference veterinary product is required before scaling to 250 mg, because the dissolution rate of chlortetracycline hydrochloride rises with decreasing tablet mass and can exceed the upper acceptance boundary in short dissolution windows. Moisture-sensitive excipients such as sorbitol or mannitol at levels above 10% w/w reduce the glass transition of the granulate and cause sticking on the roller compactor at ambient relative humidity above 50%. Processing is therefore constrained to humidity-controlled suites below 50% RH with the API dispensed under nitrogen purge if bulk storage exceeds 24 hours. Tablet coat systems that require aqueous film coating are spray-applied in a pan coater with inlet air below 60°C and bed temperature below 40°C; organic-solvent coating is used only where local VOC permits allow, because residual solvent reduction in porous chlortetracycline granulate is slower than for high-density fillers. Terminal finished product types are film-coated tablets, chewable tablets, and hard gelatin capsules, but the chewable form must avoid calcium-containing flavour bases, since calcium ions bind tetracycline at the 1,3-diketonate and reduce oral absorption.

Injectable Solution Stabilisation Without Polyvalent Cation Contact

Parenteral formulations of chlortetracycline present a narrower processing window than oral powders because terminal sterilisation choices directly affect the tetracyclic moiety. For a 50 mg/mL or 100 mg/mL injection, the API is dissolved in a non-aqueous or mixed aqueous-organic vehicle, often polyethylene glycol 400 and propylene glycol, with water for injection used only after the stability of the specific batch matrix has been established. The addition ratio of API to vehicle is derived from a formulation-specific solubility and degradation study, not from a transferable general formula; published peer-reviewed data for this specific configuration are limited, and each dossier must establish its own pH range, usually on the acid side of neutral for hydrochloride stability but not so low as to cause injection-site precipitation. Chloride-containing vehicles are avoided when possible because the high chloride load can drive recrystallisation; sodium chloride is specifically excluded to prevent the common ion effect. Sterilising-grade filtration through a 0.22 µm membrane is preferred over autoclaving because thermal exposure above 121°C for 15 minutes produces anhydrotetracycline and 4-epimer impurities beyond the limits set in the current pharmacopoeial monograph. Filling is done aseptically into low-density polyethylene or glass vials washed with water for injection free from calcium, magnesium, iron, and zinc; any trace divalent cation contact during filling forms highly coloured metal-tetracycline complexes visible as dark bands at the fill line. Compliance for injectable dosage forms is driven by USP <1> injections, USP <71> sterility, USP <85> bacterial endotoxins, and 21 CFR Part 211 manufacturing controls, with EU products under Regulation (EU) 2019/6 and the relevant Ph. Eur. 2.6.1 and 2.6.14 general chapters for sterility and endotoxins. Filterability of a 50 mg/mL non-aqueous solution through a 0.22 µm polyvinylidene fluoride membrane falls as viscosity rises above 60 mPa·s at 20°C; formulations with high propylene glycol fractions may require pre-warming to 30°C before filtration. The filling line is configured for nitrogen purging of the headspace because dissolved oxygen shortens the induction period before colour change from amber to dark brown. Leachable testing on elastomeric closures follows the storage orientation study; because chlortetracycline can extract sulfonamide-like accelerators from rubber stoppers into the solution, only ethylene propylene diene monomer or fluoropolymer-coated stoppers are qualified. In-process checks include filter integrity by forward-flow test after filling, pH measurement to ±0.05 units, and visible inspection against a black-and-white background for metal complexes. Terminal finished product types are single-dose and multi-dose vials for intramuscular or subcutaneous administration in the species listed in the marketing authorisation, but not ready-to-use intravenous bags, because the chelation risk with polyvalent ions in standard saline or Ringer’s lactate solutions makes admixture stability unpredictable.

When chlortetracycline is incorporated into calf or lamb milk replacer powders, the common failure is not dry blend segregation but the reduction of oral absorption caused by milk calcium and casein binding. Tetracyclines form chelate complexes with divalent cations at the upper small intestine, and milk replacers containing 0.8–1.4% calcium on dry matter are therefore not a neutral carrier. The formulation approach for a medicated milk replacer is to dose at the upper end of the authorised range for the target species, often 10–20 mg chlortetracycline per kg bodyweight per day, and to split the daily dose over two feeds to reduce the concentration of unbound API competing with calcium. Production is done as a micro-ingredient pre-blend at 1:10 dilution into whey powder or lactose, then mixed into the full milk replacer formulation in a paddle mixer with fill ratio 60–70% and mixing time not less than 5 minutes. The pre-blend is assayed before addition because chlortetracycline hydrochloride can lose activity on the surface of highly alkaline minerals, and the finished milk replacer is sealed in moisture-barrier bags under residual moisture below 3%. Regulatory controls are the same as for oral powders in food-producing calves: Commission Regulation (EU) No 37/2010 sets the tissue MRL, the veterinary medicinal product must be authorised under Regulation (EU) 2019/6, and in the United States the route must fall under an approved chlortetracycline application with appropriate withdrawal period. Published data for this specific configuration are limited, particularly for the influence of casein concentration on absorption rate constant; where a producer requires exact pharmacokinetic parameters, a target animal study under 2019/6 is necessary. The operational boundary for drying is inlet air below 60°C because casein denaturation above this setpoint changes reconstitution behaviour and may entrap API in a hydrophobic phase. Acidification of the milk replacer with citric acid to pH 5.0–5.5 improves chlortetracycline solubility but conflicts with abomasal clotting in young calves; therefore acidified milk replacers are excluded from the registered use unless specifically developed. Terminal finished product types are medicated calf milk replacer powder, milk replacer top-dress sachets, and oral drench powders reconstituted in water or milk, but the use of milk as a diluent is restricted by the calcium interaction and requires a higher dose certainty in the bioavailability section of the dossier.

When Regional Authorisations Permit In-Feed Chlortetracycline for Aquaculture Species

Finfish and shrimp feed applications sit at the perimeter of chlortetracycline use because regulatory authorisations are not harmonised across major aquaculture jurisdictions. Where a national registration does permit in-feed chlortetracycline for bacterial disease control in fish or shrimp, the formulation must solve an aqueous leaching problem that is less prominent in terrestrial feeds. Methionine and betaine binders are insufficient to retain a water-soluble tetracycline salt during feed immersion; the active is therefore pre-coated or encapsulated in a lipid or alginate matrix at 2–5% w/w of the granule before blending into the extruded feed. Addition rate is species- and authorisation-specific, but the medicated feed production record must demonstrate homogeneous distribution at the registered dose, typically expressed in mg active per kg biomass per day rather than per tonne of feed, because daily feeding rates vary with water temperature and oxygen. Compliance is anchored by Codex Alimentarius risk assessment for veterinary drug residues where adopted, national aquaculture residue monitoring programmes, and HACCP systems under feed safety management; in the EU, aquaculture use is subject to the same residue control framework under Commission Regulation (EU) No 37/2010 if authorised for a food-producing species. Downstream production uses twin-screw extrusion at barrel temperatures not exceeding 90°C in the post-conditioner zone, because the encapsulated tetracycline fraction degrades rapidly above 100°C and loses 10–20% of assay during high-temperature micro-extrusion. Extrusion moisture is controlled at 20–25% in the preconditioner and the extruder barrel is vented properly; otherwise steam induces recrystallisation of the API on the pellet surface and creates a bitter surface residue that reduces palatability in shrimp. Published data for this specific configuration are limited; producers are advised to run a pilot-scale leachability study with test diet immersion in seawater at 28°C for 15 minutes, measuring water-phase chlortetracycline release by liquid chromatography before committing to commercial batch sizes. If the granule coating does not reduce the 15-minute leachability below 10% of total labelled active, the formulation is not suitable for pond feeding. Terminal finished product types are slow-sinking medicated pellets, coated top-dress granules, and lipid-coated premixes for on-farm addition, not fine powders broadcast onto water, which disperse before ingestion.